• Pneumococcal
  • Adults who have had PCV13

Which adults ages 19–64 years may receive a second dose of PPSV23 before age 65?

Either a second PPSV23 or a dose of PCV20 should be given 5 years after the first dose of PPSV23 for people age 19 through 64 years who were vaccinated with PCV13 (Prevnar 13, Pfizer) and PPSV23 and who have one of the following immunocompromising conditions:

  • Kidney disease and on maintenance dialysis
  • Kidney disease with nephrotic syndrome
  • Asplenia or splenic dysfunction
  • Congenital or acquired immunodeficiency, including B-(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)
  • Treatment with immunosuppressive drugs or radiation therapy (including treatment for Hodgkin disease, leukemias, lymphomas, malignant neoplasm, and solid organ transplant)
  • HIV infection
  • Sickle cell disease or other hemoglobinopathies
Last reviewed: April 5, 2024

This page was updated on .